Research Summary

Lisa H. Butterfield, Ph.D. is an Adjunct Professor of Microbiology and Immunology, University California San Francisco and a consultant in immuno-oncology. Her research is focused on cancer vaccines, immune profiling and cellular therapies for melanoma, hepatocellular cancer and other tumor types. Dr. Butterfield was most recently Vice President, Research and Development at the Parker Institute for Cancer Immunotherapy, where she supported cell therapy initiatives and clinical trial biospecimen and biomarker projects. Previously, she was a tenured Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh (2003-2018) and Director of the Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory. She has a PhD in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. She was the President of the Society of Immunotherapy of Cancer (SITC, 2017-2018) and a member of the SITC Executive Committee (2015-2020). She led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group (2006-2018) and collaborates on biomarker studies in many clinical trials. She has published over 185 peer-reviewed manuscripts, reviews and book chapters, and mentored over 20 students and postdocs. She co-leads the SITC Women’s Leadership Institute and is a co-Editor of the SITC textbook “Cancer Immunotherapy: Principles and Practice” 1st and 2nd editions.


Rensselaer Polytechnic Institute, Troy, New York, B.S., 05/86, Biology
University of California Los Angeles, Ph.D., 02/93, Biology
University of California Los Angeles, Postdoc fellow, 03/95, Tumor Immunology
University of California Los Angeles, Postdoc fellow, 03/97, Radiation Oncology

Honors & Awards

  • 2010-2014
    Standing member, NIH CII Study Section, Cancer Immunopathology and Immunotherapy
  • 2010
    iSBTc Team Science Recognition Award
  • 2011-present
    Editorial Board, OncoImmunology
  • 2012-2019
    Section Editor, Journal of ImmunoTherapy of Cancer; Immunotherapy Biomarkers section
  • 2016
    AAI Travel Award to the International Congress on Immunology, Melbourne, Australia
  • 2016-2023
    Member, Food and Drug Administration Cellular, Tissues and Gene Therapies Advisory Committee
  • 2018-3/2023
    Chair, Food and Drug Administration Cellular, Tissues and Gene Therapies Advisory Committee
  • 2017-2019
    Member, FNIH Drug Selection Committee for the Lung-MAP Clinical Trial
  • 2017-2018
    Member, AACR Education Committee for the 2018 Annual Meeting
  • 2019-present
    Member, PICI Scholars and Fellows Scientific Review Committee
  • 2020-present
    Member, PICI Invention Review Committee
  • 2020
    Member, PICI Revenue Initiative Committee
  • 2020
    SITC Visionary/Legacy Award

Selected Publications

  1. Maurer, DM, Adamik, J, Santos, PM, Shi, J, Shurin, MR, Kirkwood, JM, Storkus, WJ, and Butterfield, LH. Dysregulated NFκB-dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T Cell Responses in Melanoma Patients. Cancer Immunol. Res. 2020 Oct 13 CIR-20-0274 
  2. Najjar, YG, McCurry, D, Lin, H, Lin, Y, Zang, Y, Davar, D, Karunamurthy, A, Drabick, JJ. Neves, RI, Butterfield, LH, Ernstoff, MS, Puzanov, I, Skitzki, J, Bordeaux, J, Summit, I, Bender, J, Kim, JY, Chen, B, Sarikonda, G, Pahuja, A, Tsau, J, Alfonso, Z, Laing, C, Pingpank, JF, Holtzman, MP, Sander, C, Rose, A, Zarour, H, Kirkwood, JM, Tarhini, AA. Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma, Clin Cancer Res. 2021 Aug 1;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. Epub 2021 Mar 22. PMID: 33753453
  3. Storkus, WJ, Maurer, DM, Lin, Y, Ding, F, Bose, A., Lowe, DB, Rose, A, DeMark, M, Karapetyan, L Taylor, JL, Chelvanambi, M, Fecek, RJ, Filderman, JN, Looney, TJ, Miller, L, Linch, E, Lowman, GM, Kalinski, P, Butterfield, LH, Tarhini, AA Tawbi, H and Kirkwood, JM Dendritic Cell Vaccines Targeting Tumor Blood Vessel Antigens in Combination with Dasatinib Induce Therapeutic Immune Responses in Patients with Checkpoint-Refractory Advanced Melanoma, J Immunother Cancer. 2021 Nov;9(11):e003675. doi: 10.1136/jitc-2021-003675. PMID: 34782430
  4. Tarhini. AA, Lee, SJ, Tan, AC, El Naqa, IM, Hodi, FS, Butterfield, LH, LaFramboise, WA, Storkus, WJ, Karunamurthy, AD, Conejo-Garcia, J, Hwu, P, Streicher, H, Sondak, VK, Kirkwood, JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 Jan;10(1):e004310. doi: 10.1136/jitc-2021-004310. PMID: 35074904
  5. Padrón, LJ, Maurer, DM, O’Hara, MH, O’Reilly, EM, Wolff, RA, Wainberg, ZA, Ko, AH, Fisher, G, Rahma, O, Lyman, JP, Cabanski, CR, Yu, JX, Pfeiffer, SM, Spasic, M, Xu, J, Gherardini, PF, Karakunnel, J, Mick, R, Alanio, C, Byrne, KT, Hollmann, T, Moore, J, Jones, D, Tognetti, M, Chen, RO, Yang, X, Salvador, L, Wherry, EJ, Dugan, U, O’Donnell-Tormey, J, Butterfield, LH, Hubbard-Lucey, VM, Ibrahim, R, Fairchild, J, Bucktrout, S, LaVallee, TM,Vonderheide, RH. Sotigalimab, an agonistic CD40 antibody, and/or nivolumab, a PD-1 inhibitory antibody, with chemotherapy in patients with previously untreated metastatic pancreatic cancer: Distinct signatures of clinical and immune response from multi-omic biomarker analyses of the randomized Phase II PRINCE trial. Nature Medicine 2022, in press. 
  6. Saad, M, Lee, SJ; Tan, AC; El Naqa, IM; Hodi, FS; Butterfield, LH; LaFramboise, WA; Storkus, WJ; Karunamurthy, AD; Conejo-Garcia, JR; Hwu, P; Streicher, H.; Sondak, VK; Kirkwood, JM; Tarhini, AA.
  7. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 Jun 3;20(1):253. doi: 10.1186/s12967-022-03450-3.
  8. PMID: 35659704
  9. Adamik, J, Munson, PV, Hartmann, FJ, Combes, AJ, Pierre, P, Krummel, MF, Bendall, SC, Argüello, RJ, Butterfield, LH. Distinct Metabolic States Guide Maturation of Inflammatory and Tolerogenic Dendritic Cells. Nature Communications, Sep 2;13(1):5184, 2022. 
  10. Sander, CA; Rush, EA; Shi, J; Arantes, L; Tesi, RJ; Ross, MA; Calderon, MJ; Watkins, SC; Kirkwood, JM; Ferris, RL; Butterfield, LH; Vujanovic, L.. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. Journal of Translational Medicine Jul 25;20(1):331, 2022.
  11. Munson, PV, Adamik, J, Hartmann, FJ, Favaro, PMB, Ho, D, Bendall, SC, Combes, AJ, Krummel, MF, Zhang, K, Kelley, RK and Butterfield, LH. Polyunsaturated fatty acid-bound Alpha Fetoprotein promotes immune suppression by altering human dendritic cell metabolism. Submitted, 2022.
  12. James S. Wilmott, Hussein Tawbi, Johnathan A Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H. Butterfield, Richard A. Scolyer, John M Kirkwood, Georgina V. Long, Michael A. Davies. Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases. Clin. Cancer Res. 2022, in press
  13. Stewart, MD, Keane, A, Butterfield, LH, Levine, BL, Thompson, B, Xue, Y, Ramsborg, C, Lee, A,  Kalos, M, Koerner, C, Moore, T, Markovic, I, Lasiter. L, Ibrahim, R, Bluestone, J, Sigal, E and Allen, J. Accelerating the Development of Innovative Cellular Therapy Products for the Treatment of Cancer. Meeting Report. Cytotherapy. 2020 Mar 18. PMID: 32199724
  14. Ascierto, PA, Fox, B, Urba, W, Anderson, AC, Atkins, MB, Borden, EC, Brahmer, J, Butterfield, LH, Cesano, A, Chen, D, de Gruijl, T, Dillman, RO, Drake, CG, Emens, LA, Gajewski ,TF, Gulley, JL, Hodi, FS, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, DG, Margolin, K, Marincola F, Mastrangelo MJ, Maus, MV, Parkinson, DR, Romero, PJ, Sondel, PM, Spranger, S, Sznol, M, Weiner, GJ, Wiggington, JM, Weber, JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 Apr;8(1).
  15. Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J. Immunother Cancer. 2020 Aug. 
  16. Wang E, Cesano A, Butterfield LH, Marincola F.J. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. J. Immunother Cancer. 2020 Oct;8(2)
  17. Gastman B, Agarwal P, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci P, Ferris R, Fong Y,  Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi K, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff Jr. CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CCS, Kaufman HL Defining best practices for tissue procurement in immuno-oncology clinical trials: Consensus statement from the Society for Immunotherapy of Cancer Surgery Committee JITC 2020
  18. Ascierto PA, Brody J, Butterfield LH, Finn OJ, Goldberg J, Perrone F, Sullivan RJ, Fox BA, Hwu P, Puzanov I. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2020. J. Translational Med. 2021 Apr.
  19. Bayless, NL, Bluestone, JA, Bucktrout, S, Butterfield, LH, Jaffee, EM, Koch, CA, Roep, BO, Sharpe, AH, Murphy, WJ, Villani, AC, Walunas, TL. Development of Preclinical and Clinical Models for Immune-related Adverse Events Following Checkpoint Immunotherapy: A Perspective from SITC and AACR. JITC, 2021 Sep;9(9):e002627. doi: 10.1136/jitc-2021-002627.
  20. Karasarides, M, Cogdill, AP, Robbins, PB, Bowden, M, Burton, EM, Butterfield, LH, Cessano, A, Hammer, C, Haymaker, CL, Horak, CE, McGee, HM, Monette, A, Rudqvist, NP, Spencer, CN, Sweis, RF, Vincent, BG, Wennerberg, E, Yuan, J, Zappasodi, R, Hubbard Lucey, VM, Wells, DK, LaVallee, TL. Hallmarks of Resistance to Immune Checkpoint Inhibitors. Cancer Immunology Research, Cancer Immunol Res (2022) 10 (4): 372–383.
  21. Munson, PV, Adamik, J and Butterfield, LH. Immune modulatory impact of alpha-fetoprotein.  Trends Immunol. 2022 Jun;43(6):438-448. doi: 10.1016/ Epub 2022 May 9. PMID: 35550875 
  22. Brown, CE Bucktrout, S, Butterfield, LH, Futer, O, Galanis, E, Hormigo, A, Lim, M, Okada, H, Prins, R, Marr, SS, and Tanner, K. The Future of Cancer Immunotherapy for Brain Tumors: A Collaborative Workshop. J Transl Med. 2022 May 23;20(1):236. doi: 10.1186/s12967-022-03438-z. PMID: 35606815
  23. Adamik, J and Butterfield, LH. What’s Next for Cancer Vaccines? invited viewpoint for special IO issue, Sci Transl Med. 2022 Nov 9;14(670):eabo4632
  24. Bucktrout S.L, Banovich N.E., Butterfield L.H., Cimen Bozkus C., Giles J.R., Good Z., Goodman D., Jonsson V, Lareau C., Marson A., Maurer D.M, Munson P.V, Stubbington M, Taylor S., Cutchin A, A Roadmap for Immunotherapeutic Development by Single Cell Technologies: Meeting Report. Nat Med. 2022 Sep;28(9):1761-1764.

Go to UCSF Profiles, powered by CTSI